MA53983A - Composés d'hétéroaryle carboxamide à 5 chaînons pour le traitement du vhb - Google Patents
Composés d'hétéroaryle carboxamide à 5 chaînons pour le traitement du vhbInfo
- Publication number
- MA53983A MA53983A MA053983A MA53983A MA53983A MA 53983 A MA53983 A MA 53983A MA 053983 A MA053983 A MA 053983A MA 53983 A MA53983 A MA 53983A MA 53983 A MA53983 A MA 53983A
- Authority
- MA
- Morocco
- Prior art keywords
- hbv
- treatment
- member heteroaryl
- carboxamide compounds
- heteroaryl carboxamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748906P | 2018-10-22 | 2018-10-22 | |
| US201962858790P | 2019-06-07 | 2019-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53983A true MA53983A (fr) | 2021-12-15 |
Family
ID=68610300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053983A MA53983A (fr) | 2018-10-22 | 2019-10-22 | Composés d'hétéroaryle carboxamide à 5 chaînons pour le traitement du vhb |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11560370B1 (fr) |
| EP (1) | EP3870296A1 (fr) |
| JP (1) | JP2022508953A (fr) |
| KR (1) | KR20210095143A (fr) |
| CN (1) | CN113195055A (fr) |
| AU (1) | AU2019364352A1 (fr) |
| BR (1) | BR112021007602A2 (fr) |
| CA (1) | CA3117449A1 (fr) |
| IL (1) | IL282433A (fr) |
| MA (1) | MA53983A (fr) |
| MX (1) | MX2021004580A (fr) |
| PH (1) | PH12021550887A1 (fr) |
| SG (1) | SG11202104086PA (fr) |
| TW (1) | TW202028190A (fr) |
| WO (1) | WO2020086533A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111205264A (zh) * | 2020-02-25 | 2020-05-29 | 成都睿智化学研究有限公司 | 一种合成同位羟基和甲磺酰甲基化合物的新方法 |
| EP4139000A1 (fr) * | 2020-04-22 | 2023-03-01 | Assembly Biosciences, Inc. | Composés de pyrazole carboxamide pour le traitement du vhb |
| WO2023069547A1 (fr) * | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | Composés d'hétéroaryle carboxamide à 5 chaînons pour le traitement du vhb |
| AU2022370483A1 (en) * | 2021-10-20 | 2024-05-02 | Assembly Biosciences, Inc. | Novel crystalline forms |
| WO2023105481A1 (fr) * | 2021-12-10 | 2023-06-15 | Assembly Biosciences, Inc. | Compositions pharmaceutiques pour le traitement du vhb |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106166157B (zh) | 2011-07-01 | 2019-08-02 | 巴鲁·S·布隆伯格研究所 | 作为防乙型肝炎病毒感染的抗病毒剂的氨磺酰苯甲酰胺衍生物 |
| WO2013010069A1 (fr) | 2011-07-13 | 2013-01-17 | Indiana University Research And Technology Corporation | Protéine structurale virale modifiée ayant une activité antivirale |
| US9233933B2 (en) | 2012-01-06 | 2016-01-12 | Janssen Sciences Ireland Uc | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis B |
| BR112015004192B1 (pt) | 2012-08-28 | 2021-02-09 | Janssen Sciences Ireland Uc | sulfamoíl-arilamidas, composição farmacêutica que os compreende e uso das mesmas no tratamento da hepatite b |
| UA115069C2 (uk) | 2012-08-28 | 2017-09-11 | ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі | Конденсовані біциклічні похідні сульфамоїлу та їх застосування як лікарських препаратів для лікування гепатиту b |
| PE20150776A1 (es) | 2012-09-10 | 2015-05-21 | Hoffmann La Roche | 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b |
| SG11201503475WA (en) | 2012-11-09 | 2015-05-28 | Univ Indiana Res & Tech Corp | Alternative uses for hbv assembly effectors |
| NZ708392A (en) | 2012-12-06 | 2020-05-29 | Baruch S Blumberg Inst | Functionalized benzamide derivatives as antiviral agents against hbv infection |
| SG10201803698UA (en) | 2012-12-27 | 2018-06-28 | Univ Drexel | Novel antiviral agents against hbv infection |
| WO2014131847A1 (fr) | 2013-02-28 | 2014-09-04 | Janssen R&D Ireland | Sulfamoyl-arylamides et leur utilisation en tant que médicaments pour le traitement de l'hépatite b |
| BR112015025052A2 (pt) | 2013-04-03 | 2021-07-06 | Janssen Sciences Ireland Uc | derivados de n-fenil-carboxamida e o seu uso como medicamentos para o tratamento da hepatite b |
| WO2014184328A1 (fr) | 2013-05-17 | 2014-11-20 | F. Hoffmann-La Roche Ag | Héteroaryldihydropyrimidines pontées en position 6 pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b |
| EA035500B1 (ru) | 2013-05-17 | 2020-06-25 | Янссен Сайенсиз Айрлэнд Юси | Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| EP3357906B1 (fr) | 2013-07-25 | 2019-12-04 | Janssen Sciences Ireland Unlimited Company | Dérivés de pyrrolamide substitués de glyoxamide et leur utilisation comme médicaments pour le traitement de l'hépatite b |
| CN105980378B (zh) | 2014-02-06 | 2019-09-27 | 爱尔兰詹森科学公司 | 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
-
2019
- 2019-10-22 US US17/287,681 patent/US11560370B1/en active Active
- 2019-10-22 JP JP2021547054A patent/JP2022508953A/ja active Pending
- 2019-10-22 BR BR112021007602-6A patent/BR112021007602A2/pt unknown
- 2019-10-22 CN CN201980082985.8A patent/CN113195055A/zh active Pending
- 2019-10-22 WO PCT/US2019/057362 patent/WO2020086533A1/fr active Application Filing
- 2019-10-22 MA MA053983A patent/MA53983A/fr unknown
- 2019-10-22 AU AU2019364352A patent/AU2019364352A1/en active Pending
- 2019-10-22 MX MX2021004580A patent/MX2021004580A/es unknown
- 2019-10-22 SG SG11202104086PA patent/SG11202104086PA/en unknown
- 2019-10-22 CA CA3117449A patent/CA3117449A1/fr active Pending
- 2019-10-22 EP EP19805797.8A patent/EP3870296A1/fr active Pending
- 2019-10-22 TW TW108138129A patent/TW202028190A/zh unknown
- 2019-10-22 KR KR1020217015135A patent/KR20210095143A/ko unknown
-
2021
- 2021-04-19 IL IL282433A patent/IL282433A/en unknown
- 2021-04-21 PH PH12021550887A patent/PH12021550887A1/en unknown
-
2022
- 2022-11-17 US US17/989,237 patent/US20240150324A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210095143A (ko) | 2021-07-30 |
| US11560370B1 (en) | 2023-01-24 |
| CA3117449A1 (fr) | 2020-04-30 |
| AU2019364352A1 (en) | 2021-06-03 |
| MX2021004580A (es) | 2021-09-08 |
| EP3870296A1 (fr) | 2021-09-01 |
| TW202028190A (zh) | 2020-08-01 |
| SG11202104086PA (en) | 2021-05-28 |
| PH12021550887A1 (en) | 2022-02-21 |
| US20240150324A1 (en) | 2024-05-09 |
| BR112021007602A2 (pt) | 2021-07-27 |
| WO2020086533A1 (fr) | 2020-04-30 |
| CN113195055A (zh) | 2021-07-30 |
| IL282433A (en) | 2021-06-30 |
| JP2022508953A (ja) | 2022-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53983A (fr) | Composés d'hétéroaryle carboxamide à 5 chaînons pour le traitement du vhb | |
| FR22C1063I2 (fr) | Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih | |
| MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
| MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
| MA53661A (fr) | Agonistes du récepteur farnésoïde x pour le traitement d'une maladie | |
| MA51916A (fr) | Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide | |
| MD3573983T2 (ro) | N-[4-fluoro-5-[[(2S,4S)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamidă în calitate de inhibitor OGA | |
| MA45052A (fr) | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille | |
| MA52942A (fr) | Composés inhibiteurs d'oga | |
| MA43168A (fr) | Dérivés de n-[2-(1-benzylpipéridin-4-yl)éthyl]-4-(pyrazin-2-yl)-pipérazine-1-carboxamide et composés apparentés en tant qu'antagonistes du récepteur muscarinique 4 (m4) pour le traitement de maladies neurologiques | |
| MA52939A (fr) | Composés inhibiteurs d'oga | |
| MA55148A (fr) | Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance | |
| MA43872A (fr) | Procédé de traitement d'une glomérulopathie à c3 | |
| MA44737A (fr) | Compositions pour le traitement de troubles liés à l'hyperkératose | |
| MA54229A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp | |
| MA55325A (fr) | Composés pour le traitement de maladies pd-l1 | |
| MA49906A (fr) | Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie | |
| MA51046A (fr) | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| MA44864A (fr) | Trithérapie pour le traitement d'une maladie intestinale inflammatoire | |
| MA51672A (fr) | Composés destinés au traitement des troubles kinases-dépendants | |
| MA55720A (fr) | Polythérapie pour le traitement d'une infection par le virus de l'hépatite b | |
| MA56114A (fr) | Composés pour le traitement de troubles dépendant de la kinase | |
| MA55917A (fr) | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie |